Objectives. These guidelines are based on a first edition that was published in 2004, and
have been edited and updated with the available scientific evidence up to October 2012 …

Abstract Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance
in psychoses, mainly schizophrenia spectrum disorders. We aimed to summarize available …

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C,
MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN …

Abstract The British Association for Psychopharmacology guidelines specify the scope and
target of treatment for bipolar disorder. The second version, like the first, is based explicitly …

Poor medication adherence is a pervasive problem that causes disability and suffering as
well as extensive financial costs among individuals with bipolar disorder (BD). Barriers to …

Background Mood recurrences in bipolar disorder (BD) are often associated with poor
treatment adherence. Despite long-acting injectable antipsychotics (LAIs) may favor …

Although the most distinctive clinical feature of bipolar disorder is the pathologically elevated
mood, it does not usually constitute the prevalent mood state of bipolar illness. The majority …

BACKGROUND: Asenapine is approved in the United States for acute treatment of manic or
mixed episodes of bipolar I disorder with or without psychotic features. We report the results …

The efficacy and safety of risperidone long-acting injectable (LAI) for preventing recurrence
of mood episodes in patients with bipolar I disorder was evaluated in a randomized, placebo …

The phenomenon of treatment-resistant depression (TRD), described as the occurrence of
an inadequate response after an adequate treatment with antidepressant agents (in terms of …